Archives
-
4-Hydroxytamoxifen Protocol and QC Guide
2026-10-01
4-Hydroxytamoxifen (SKU B6167) provides a DMSO-compatible estrogen receptor modulator for controlled receptor, cancer-cell, apoptosis, and cardiac myocyte workflows. It should not be selected for protocols requiring aqueous or ethanol solubility, and solution stability should not be assumed during long-term storage.
-
Omeprazole A2845: Practical Research Protocol
2026-10-01
Omeprazole (SKU A2845) provides a research-grade H+,K+-ATPase inhibitor for controlled gastric acid secretion research, antiulcer activity studies, and related preclinical assay workflows. This guide addresses solubility, storage, controls, and interpretation; it is not a clinical, diagnostic, or dosing guide and does not substitute for matched paper evidence.
-
GS967 and the Late Sodium Current in Cardiac Aging
2026-09-30
Late sodium current is emerging as a mechanistic bridge between electrical instability, calcium overload, delayed relaxation, and age-associated cardiac dysfunction. This article examines how GS967 can help translational researchers connect ventricular myocyte electrophysiology with tissue-level arrhythmia phenotypes, while outlining assay design, competitive positioning, and the limits of preclinical interpretation.
-
Lipid Nanoparticles in Cancer Immunotherapy
2026-09-30
This 2025 review explains how lipid nanoparticles can address degradation, cellular uptake, biodistribution, and toxicity barriers in nucleic acid cancer immunotherapy. Its main contribution is an integrated framework connecting cargo selection, nanoparticle properties, immune-cell delivery, and translational limitations rather than introducing a new formulation.
-
2-Deoxy-D-Glucose and T-Cell Immunometabolism in OLP
2026-09-29
The reference study shows that oral lichen planus-derived T cells exhibit elevated glycolytic and mTOR-associated activity, and that 2-deoxy-D-glucose reduces their proliferation and ability to trigger keratinocyte apoptosis. Rapamycin strengthened these effects, supporting a mechanistic connection between glycolytic metabolism, mTOR signaling, T-cell survival, and epithelial injury.
-
RGFP966: HDAC3 Inhibition Meets HO-1 Assays
2026-09-29
RGFP966 is a selective HDAC3 inhibitor that can help dissect how chromatin regulation influences cellular stress responses. This article presents a practical, activity-centered framework for pairing RGFP966 with the live-cell HO-1 probe AMC-Hem while separating established findings from testable experimental hypotheses.
-
CRISPR-Cas Antimicrobial Therapy: Evidence and Limits
2026-09-28
The 2025 review by Yang and colleagues frames CRISPR-Cas as a programmable antimicrobial strategy for selectively eliminating pathogens, removing antibiotic-resistance genes, and engineering bacteriophages. Its main practical contribution is an integrated analysis of CRISPR mechanisms, delivery vehicles, phage applications, and the biological barriers that still separate promising laboratory concepts from deployable therapies.
-
TSA Beyond Tumor Cells: Epigenetics Meets Immunity
2026-09-28
Trichostatin A (TSA) is best understood not simply as a way to alter histone acetylation, but as a context-dependent probe of cell state. This article connects its established cancer-research applications with findings in stressed dendritic cells, then translates those insights into practical experimental choices—while keeping preclinical promise distinct from clinical evidence.
-
SIRT1/2 Inhibitor IV: Practical Research Workflows
2026-09-27
Use SIRT1/2 Inhibitor IV (cambinol) to test how sirtuin activity intersects with lactate signaling, protein modification, and cell phenotype. The guide pairs an emerging astrocyte OGD/R application with established cancer-model observations, while highlighting controls needed to interpret a dual, high-micromolar inhibitor.
-
Belinostat (PXD101): In Vitro Assay Workflow
2026-09-26
Use Belinostat (PXD101) to probe how pan-HDAC inhibition changes histone acetylation, proliferation, cell-cycle distribution, and cell killing in cancer models. A paired-readout workflow helps distinguish growth arrest from loss of viable cells—two drug responses that a single endpoint can blur.
-
BCL-2 Targeting Across Heterogeneous CRPC
2026-09-25
Single-cell imaging and preclinical models show that BCL-2-positive prostate cancer cells increase in castration-resistant disease, including cells with different androgen-receptor states. The study links AR inhibition to BCL-2 derepression and provides early clinical evidence that combining enzalutamide with venetoclax may reduce circulating tumor cells in some patients.
-
3X (DYKDDDDK) Peptide for Protein Workflows
2026-09-25
Use the 3X (DYKDDDDK) Peptide as a soluble competitor to help release FLAG-tagged proteins from affinity matrices and support clean downstream analysis. This workflow-focused guide connects tag-based protein handling to kinase-substrate research while flagging the controls needed for phosphorylation and metal-sensitive assays.
-
ATRX Loss and the Translational Case for RTK Inhibition
2026-09-24
ATRX deficiency may help explain why some high-grade glioma cells respond differently to receptor tyrosine kinase and PDGFR inhibitors. This article examines the mechanistic rationale, experimental considerations, and clinical-trial implications—and offers a cautious framework for evaluating AZ 10417808 without assuming an unverified target or study role.
-
Cecal Omics After E. tenella Treatment in Chickens
2026-09-24
This study paired 16S rRNA gene sequencing with LC-MS/MS metabolomics to examine how Eimeria tenella infection and treatment reshape the chicken cecal environment. Ethanamizuril was associated with a microbiota profile interpreted as more stable, while sulfachlorpyridazine was associated with lower Escherichia-Shigella; the low-dose combination had limited effects under the conditions tested.
-
DCFH-DA Workflows for Cellular ROS Assays
2026-09-23
Use DCFH-DA to compare intracellular oxidative activity across microscopy, flow cytometry, and plate-reader workflows—not to identify a specific ROS or its source. A granulosa-cell study of LSKL and THBS1 offers a practical disease-model example, with controls and optimization tips for making fluorescence results more interpretable.